Newsbenzinga
Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder
· Published
Article summary
Incyte reports Phase 1/2 latarcibart data showing lower bleeding rates and favorable safety in patients with von Willebrand disease.
An excerpt from the original article.
Comments —
Loading comments…